Fadi Nasr

Fadi Nasr

Auto-generated profile, based on publicly available information

Fadi Nasr

Department of Hematology-Oncology

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
ERElie Rassy
Elie Rassy
HKHampig Raphael Kourie
Hampig Raphael Kourie
WNWilliam Nehme
William Nehme
SGSamuel Georges
Samuel Georges
EHElie Haddad
Elie Haddad
FNFadi Nasr
Fadi Nasr

15 November 2024 in Future Oncology
Verified
Journal Article
Closed access
ATArafat Tfayli
Arafat Tfayli
HGHady Ghanem
Hady Ghanem
FNFadi Nasr
Fadi Nasr
HKHampig Raphael Kourie
Hampig Raphael Kourie
GHGeorges El Hachem
Georges El Hachem
JKJoseph Kattan
Joseph Kattan
Treatment of non-small-cell lung cancers (NSCLC) has evolved over the last decade. According to studies, the use of targeted therapies has significantly increased the life expectancy of patients. Moreover, ALK-tyrosine kinase inhibitors (ALK-TKIs) have improved clinical outcomes. In Lebanon, translating recommendations into clinical practice remains challenging. A Lebanese expert panel of oncologists was convened to describe the management paradigm and the clinical evidence supporting the optimal use of next-generation TKIs in patients with ALK-rearranged NSCLC and to provide an expert overview of local challenges and recommendations for optimizing the management of advanced NSCLC in Lebanese patients. The experts agreed that these recommendations should be part of a healthcare strategy to be implemented at the national level.